@EgidiusLambrech E Lambrechts

E Lambrechts posts on X about $gmab, $jnj, $abbv, acasunlimab the most. They currently have [---] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

[--] Week [------] -99%
[--] Month [---------] +273,994%
[--] Months [---------] +35,382%
[--] Year [---------] +13,939%

Mentions: [--] #

[--] Week [--] -10%
[--] Month [--] +93%
[--] Months [---] +148%
[--] Year [---] +86%

Followers: [---] #

[--] Week [---] no change
[--] Month [---] +0.29%
[--] Months [---] +0.29%
[--] Year [---] +2.40%

CreatorRank: undefined #

Social Influence

Social category influence stocks 30.95% countries 13.49% finance 4.76% currencies 3.97% financial services 0.79%

Social topic influence $gmab #2, $jnj 10.32%, $abbv #66, acasunlimab 8.73%, target 7.94%, ukraine 7.94%, $mrus 6.35%, to the 5.56%, rating 5.56%, kyiv 3.97%

Top accounts mentioned or mentioned by @genmab @jacobplieth @moffittnews @luciusjameson @apexonco @kyivpost @repdonbacon @biblapmatch @amaymd @wallstsai @biohazard3737 @eurobiotechnews @streetinsider @davidmygind @ibdinvestors @nicktimiraos @daractenus @reuters @cision @bymadeleinea

Top assets mentioned Johnson & Johnson (JNJ) AbbVie Inc (ABBV) Merus N.V. Common Shares (MRUS) Novartis AG (NVS) Pfizer, Inc. (PFE) Amgen, Inc. (AMGN) Novo-Nordisk (NVO) Bank of America (BAC) Frontline Ltd. (FRO)

Top Social Posts

Top posts by engagements in the last [--] hours

"#Genmab bringing another new antibody to the clinic: Trial to Evaluate the Safety and Preliminary Efficacy of #GEN1079 in Participants With Advanced Solid Tumors $GMAB https://clinicaltrials.gov/study/NCT07387068 https://clinicaltrials.gov/study/NCT07387068"
X Link 2026-02-04T15:17Z [---] followers, [---] engagements

"Novartis : So we continue to generate additional value for #Kesimpta. We continue to progress our every 2-month formulation for Kesimpta. So I think were on a solid track with this brand to fully achieve our peak sales guidance of $6 billion plus. #Genmab $GMAB #Royalties $NVS"
X Link 2026-02-05T14:22Z [---] followers, [---] engagements

"@JacobPlieth curious to find out if in this ADC AbbVie will use the technology which they claim Profound/Genmab allegedly misappropriated from them 🍿"
X Link 2026-02-09T10:21Z [---] followers, [---] engagements

"Johnson & Johnson submits application to the European Medicines Agency for #TECVAYLI (teclistamab) in combination with #DARZALEX (daratumumab) subcutaneous formulation for patients with R/R multiple myeloma #Genmab $GMAB #DoubleRoyalties $JNJ https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-refractory-multiple-myeloma"
X Link 2026-01-06T13:34Z [---] followers, [---] engagements

"De belofte van #petosemtamab voor gevorderde of gemetastaseerde hoofd-halskanker $GMAB $MRUS Genmab https://www.mednet.nl/nieuws/de-belofte-van-petosemtamab-voor-gevorderde-of-gemetastaseerde-hoofd-halskanker/ https://www.mednet.nl/nieuws/de-belofte-van-petosemtamab-voor-gevorderde-of-gemetastaseerde-hoofd-halskanker/"
X Link 2026-01-09T16:23Z [---] followers, [---] engagements

"@biblapmatch @A_May_MD @WallStSai @Biohazard3737 Genmab already mentioned in their Q3 call 'the subQ development is an integral part of our strategy for Petosemtamab but more to come after the finalization of the transaction' and also here https://ugebrev.dk/flashnews/transcript-genmabs-praesentation-paa-jefferies-healthcare-conference-med-qa/ https://ugebrev.dk/flashnews/transcript-genmabs-praesentation-paa-jefferies-healthcare-conference-med-qa/"
X Link 2026-01-14T11:36Z [---] followers, [---] engagements

"#TECVAYLI monotherapy : superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma refractory to anti-CD38 therapy and lenalidomide $JNJ $GMAB #Genmab #Royalties Teclistamab . https://www.jnj.com/media-center/press-releases/tecvayli-monotherapy-demonstrates-superior-progression-free-and-overall-survival-versus-standard-of-care-as-early-as-first-relapse-in-patients-with-multiple-myeloma-predominantly-refractory-to-anti-cd38-therapy-and-lenalidomide"
X Link 2026-01-15T09:10Z [---] followers, [---] engagements

"Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer $GMAB #Genmab #RinatabartSesutecan https://www.oncnursingnews.com/view/why-does-rina-s-target-folate-receptor-alpha-in-endometrial-cancer- https://www.oncnursingnews.com/view/why-does-rina-s-target-folate-receptor-alpha-in-endometrial-cancer-"
X Link 2026-01-15T13:07Z [---] followers, [---] engagements

"Dr. Paul Geerts over #teclistamab-#daratumumab vs DVd/DPd bij R/R MM #Genmab $GMAB #Tecvayli #Darzalex #DoubleRoyalties . https://www.mednet.nl/congres-nieuws/dr-paul-geerts-over-teclistamab-daratumumab-vs-dvd-dpd-bij-r-r-mm/ https://www.mednet.nl/congres-nieuws/dr-paul-geerts-over-teclistamab-daratumumab-vs-dvd-dpd-bij-r-r-mm/"
X Link 2026-01-16T12:19Z [---] followers, [---] engagements

"William Blair reiterated a Buy rating on #Genmab $GMAB citing limited risk to the accelerated approval of Epkinly despite mixed trial results. Truist Financial has similarly maintained a Buy rating with a $48.00 price target Barclays Maintained Buy dkk 2.500"
X Link 2026-01-19T08:10Z [---] followers, [---] engagements

"$JNJ $GMAB #Genmab #Royalties Led by Darzalex surge J&J expects revenue to reach $100B in [----] https://t.co/PLQDlQ2ctQ Led by Darzalex surge J&J expects revenue to reach $100B in [----] https://t.co/PLQDlQ2ctQ"
X Link 2026-01-21T19:08Z [---] followers, [---] engagements

"New Genmab / Merus Ph2 trial: Study to Investigate #Petosemtamab in Adults With Metastatic Non-Small Cell #Lung Cancer $GMAB $MRUS (fyi @JacobPlieth ) https://clinicaltrials.gov/study/NCT07353957 https://clinicaltrials.gov/study/NCT07353957"
X Link 2026-01-24T10:34Z [---] followers, [---] engagements

"@EuroBiotechNews Genmab also have MCLA-129 from Merus an EGFR x c-MET Biclonics and just opened a new Petosemtamab trial in NSCLC ; both possibly competing with GEN1286. By the way their last JP Morgan presentation shows Rina-S is expected to launch already in 2027: https://clinicaltrials.gov/study/NCT07353957 https://clinicaltrials.gov/study/NCT07353957"
X Link 2026-01-27T09:50Z [---] followers, [---] engagements

"DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible $JNJ $GMAB #Genmab #Royalties https://prn.to/49LtU5f https://prn.to/49LtU5f"
X Link 2026-01-28T11:27Z [---] followers, [---] engagements

"H.C. Wainwright has reiterated a Buy rating and $39.00 price target on Genmab A/S ( $GMAB ) following FDA approval of DARZALEX FASPRO for newly-diagnosed multiple myeloma patients. https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885 https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885"
X Link 2026-01-28T13:03Z [---] followers, [---] engagements

"#Genmab bringing a new antibody to the clinic: First-in-human (FIH) Trial of #GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) $GMAB https://clinicaltrials.gov/study/NCT07384715 https://clinicaltrials.gov/study/NCT07384715"
X Link 2026-02-03T14:35Z [---] followers, [---] engagements

"How Does Rina-S Work in Patients With Pretreated #Endometrial Cancer #Genmab $GMAB rinatabart sesutecan https://www.oncnursingnews.com/view/how-does-rina-s-work-in-patients-with-pretreated-endometrial-cancer- https://www.oncnursingnews.com/view/how-does-rina-s-work-in-patients-with-pretreated-endometrial-cancer-"
X Link 2026-02-05T17:58Z [---] followers, [---] engagements

"$GMAB $ABBV Genmab AbbVie #Epkinly 📈 Epcoritamab continues to show activity across the #CLL disease spectrum extending its reach into Richter transformation. 📝 Read more from an analysis of the EPCORE CLL-1 trial with insight from Jose Sandoval Sus MD of @MoffittNews. ➡ https://t.co/5c1X9Vt4Rf https://t.co/c2YqphY3K8 📈 Epcoritamab continues to show activity across the #CLL disease spectrum extending its reach into Richter transformation. 📝 Read more from an analysis of the EPCORE CLL-1 trial with insight from Jose Sandoval Sus MD of @MoffittNews. ➡ https://t.co/5c1X9Vt4Rf"
X Link 2026-02-09T14:57Z [---] followers, [----] engagements

"With #Tepezza sales still stagnant Amgen has a plan to boost the newly acquired TED drug Q3 '23 $453mn #Teprotumumab $GMAB #Genmab #Royalties https://www.fiercepharma.com/pharma/tepezza-sales-still-stagnant-amgen-has-plan-boost-newly-acquired-ted-drug https://www.fiercepharma.com/pharma/tepezza-sales-still-stagnant-amgen-has-plan-boost-newly-acquired-ted-drug"
X Link 2023-10-31T15:41Z [---] followers, [---] engagements

"Amgen Files TED Drug #Tepezza in Japan Amgen filed a new drug application in Japan for #teprotumumab which it picked up through the acquisition of Horizon Therapeutics for the treatment of active thyroid eye disease $GMAB #Genmab #Royalties $AMGN https://pj.jiho.jp/article/250263 https://pj.jiho.jp/article/250263"
X Link 2024-01-17T08:14Z [---] followers, [---] engagements

"RBC Capital analyst Alistair Campbell upgraded #Genmab A/S ( $GMAB) from Sector Perform to #Outperform with a price target DKK [----] via @Street_Insider https://www.streetinsider.com/Analyst+Comments/RBC+Capital+Upgrades+Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+to+Outperform/23461150.html https://www.streetinsider.com/Analyst+Comments/RBC+Capital+Upgrades+Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+to+Outperform/23461150.html"
X Link 2024-07-15T08:27Z [---] followers, [---] engagements

"@JacobPlieth @ApexOnco Do you think Genmab would be allowed to develop PRO1286 the bispecific EGFR x cMET ADC they took over from Profound within the rules of the contract they have with JNJ on amivantamab I understand $GMAB received an IND to start a trial in China for this asset"
X Link 2024-10-04T07:23Z [---] followers, [---] engagements

"Zai Lab Announces Positive Topline Results for #TIVDAK in the #China Subpopulation of the Global Phase [--] innovaTV [---] Trial in Patients with Recurrent or Metastatic Cervical Cancer $GMAB $PFE #Genmab #Pfizer Tisotumab Vedotin https://www.businesswire.com/news/home/20250115437262/en/Zai-Lab-Announces-Positive-Topline-Results-for-TIVDAK-in-the-China-Subpopulation-of-the-Global-Phase-3-innovaTV-301-Trial-in-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer"
X Link 2025-01-15T13:16Z [---] followers, [---] engagements

"Novo Nordisk : Once-weekly #Mim8 is well-tolerated and efficacious in children living with #haemophilia A with and without inhibitors $NVO $NOVOB $GMAB s DuoBody technology #Genmab #Denecimig https://finance.yahoo.com/news/novo-nordisk-once-weekly-mim8-074500180.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/novo-nordisk-once-weekly-mim8-074500180.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"
X Link 2025-02-07T08:50Z [---] followers, [----] engagements

"Gunstige uitkomsten profylaxe met #Mim8 bij hemofilie A-patinten $NVO $NOVOB $GMAB s DuoBody technology #Genmab #Denecimig https://www.mednet.nl/congres-nieuws/gunstige-uitkomsten-profylaxe-met-mim8-bij-hemofilie-a-patienten/ https://www.mednet.nl/congres-nieuws/gunstige-uitkomsten-profylaxe-met-mim8-bij-hemofilie-a-patienten/"
X Link 2025-02-11T09:00Z [---] followers, [---] engagements

"Optimal Dosing Regimen for #Epcoritamab aSubcutaneous Bispecific Antibody in Relapsed or Refractory Large B-Cell Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly #Tepkinly https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3588 https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3588"
X Link 2025-02-15T12:06Z [---] followers, [---] engagements

"U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for high-risk #smoldering multiple myeloma $JNJ $GMAB #Genmab #ODAC https://www.jnj.com/media-center/press-releases/u-s-fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-benefit-risk-profile-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma"
X Link 2025-05-21T07:05Z [---] followers, [---] engagements

"TECVAYLI and DARZALEX FASPRO-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma #Genmab $GMAB $JNJ https://prn.to/4mlcJdF https://prn.to/4mlcJdF"
X Link 2025-09-19T13:18Z [---] followers, [---] engagements

"Deense farmaceut verrast met overname #Merus: #Genmab is anderen te snel af geweest. $GMAB $MRUS #BNR https://www.bnr.nl/nieuws/tech-innovatie/10584093/deense-farmaceut-verrast-met-overname-merus-genmab-is-anderen-te-snel-af-geweest https://www.bnr.nl/nieuws/tech-innovatie/10584093/deense-farmaceut-verrast-met-overname-merus-genmab-is-anderen-te-snel-af-geweest"
X Link 2025-09-29T17:40Z [---] followers, [---] engagements

"Novo Nordisk has submitted an application to the FDA seeking approval of #Mim8 for the treatment of people with hemophilia A. $NOVO $GMAB #Genmab #Royalties #denecimig https://hemophilianewstoday.com/news/novo-nordisk-asks-fda-approve-hem-a-injection-therapy-mim8/utm_source=twitter&utm_medium=shared https://hemophilianewstoday.com/news/novo-nordisk-asks-fda-approve-hem-a-injection-therapy-mim8/utm_source=twitter&utm_medium=shared"
X Link 2025-10-01T05:37Z [---] followers, [---] engagements

"Is #Genmabs New Asset the Next Big Bet in PD-1 Combination Therapy for Head and Neck Cancer Petosemtamab EGFRLGR5 $GMAB https://www.geneonline.com/category/biotech/rd/ https://www.geneonline.com/category/biotech/rd/"
X Link 2025-10-01T08:30Z [---] followers, [---] engagements

"#Lundbeck to showcase #amlenetug Phase [--] MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders [----] #Genmab $GMAB #Royalties https://prn.to/48cDNbY https://prn.to/48cDNbY"
X Link 2025-10-02T07:56Z [---] followers, [---] engagements

"UBS Raises Price Target for #Genmab to [----] Danish Kroner Reiterates Buy $GMAB #MarketScreener https://www.marketscreener.com/news/ubs-raises-price-target-for-genmab-to-2-700-danish-kroner-reiterates-buy-ce7d5bdcdd81f523utm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/news/ubs-raises-price-target-for-genmab-to-2-700-danish-kroner-reiterates-buy-ce7d5bdcdd81f523utm_source=twitter&utm_medium=social&utm_campaign=share"
X Link 2025-10-06T12:00Z [---] followers, [---] engagements

"#Merus Announces #Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics $GMAB #Genmab https://ir.merus.nl/news-releases/news-release-details/merus-announces-petosemtamab-metastatic-colorectal-cancer https://ir.merus.nl/news-releases/news-release-details/merus-announces-petosemtamab-metastatic-colorectal-cancer"
X Link 2025-10-13T16:36Z [---] followers, [---] engagements

"#Merus Announces Publication of an Abstract on #Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -very early data more on October [--] $GMAB #Genmab https://ir.merus.nl/news-releases/news-release-details/merus-announces-publication-abstract-petosemtamab-metastatic https://ir.merus.nl/news-releases/news-release-details/merus-announces-publication-abstract-petosemtamab-metastatic"
X Link 2025-10-14T12:55Z [---] followers, [---] engagements

"$GMAB #Genmab $MRUS Small N and more data to come at plenary oral later this month but Peto in mCRC (efficacy evaluable): 1L combo 3/3 ORR 100% 2L combo 4/8 ORR 50% 3L mono one PR in this late line . https://t.co/3BLMGgrFV9 $MRUS Small N and more data to come at plenary oral later this month but Peto in mCRC (efficacy evaluable): 1L combo 3/3 ORR 100% 2L combo 4/8 ORR 50% 3L mono one PR in this late line . https://t.co/3BLMGgrFV9"
X Link 2025-10-14T14:11Z [---] followers, [---] engagements

"Teclistamab $JNJ $GMAB #Genmab Tecvayli Myeloma Drug Performs Well in Autoimmune Diseases https://t.co/Kw7HM0GOX4 Another possible indication for Teclistamab. Safety must be considered Myeloma Drug Performs Well in Autoimmune Diseases https://t.co/Kw7HM0GOX4 Another possible indication for Teclistamab. Safety must be considered"
X Link 2025-10-16T07:06Z [---] followers, [---] engagements

"#Petosemtamab shows first colorectal promise $MRUS $GMAB #Genmab https://www.oncologypipeline.com/apexonco/petosemtamab-shows-first-colorectal-promise https://www.oncologypipeline.com/apexonco/petosemtamab-shows-first-colorectal-promise"
X Link 2025-10-16T07:19Z [---] followers, [---] engagements

"$GMAB #Genmab Tecvayli/Darzalex combo $JNJ claims a Tecvayli/Darzalex combo win with a PFS & OS benefit in Majestec-3 https://t.co/ysYcaJCjF8 $JNJ claims a Tecvayli/Darzalex combo win with a PFS & OS benefit in Majestec-3 https://t.co/ysYcaJCjF8"
X Link 2025-10-16T12:30Z [---] followers, [---] engagements

"Promising Clinical Developments in #Genmabs Portfolio Reinforce Buy Rating Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab and keeping the price target at $40.00. $GMAB https://www.tipranks.com/news/ratings/promising-clinical-developments-in-genmabs-portfolio-reinforce-buy-rating-ratings#google_vignette https://www.tipranks.com/news/ratings/promising-clinical-developments-in-genmabs-portfolio-reinforce-buy-rating-ratings#google_vignette"
X Link 2025-10-21T11:23Z [---] followers, [---] engagements

"Fast and confident follow up by #Genmab on the Merus takeover. $GMAB clearly has no doubts on petosemtamab. Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. https://ir.genmab.com/news-releases/news-release-details/genmab-commences-tender-offer-all-issued-and-outstanding-common https://ir.genmab.com/news-releases/news-release-details/genmab-commences-tender-offer-all-issued-and-outstanding-common"
X Link 2025-10-21T17:09Z [---] followers, [---] engagements

"@LuciusJameson I assume Genmab has the deepest understanding of Rybrevant capabilities after JNJ they even created both arms. Merus itself has MCLA-129 -EGFR x c-MET biclonics which data Genmab will have seen"
X Link 2025-10-21T18:07Z [---] followers, [---] engagements

"@LuciusJameson in addition they have GEN1286 from Profound which they said was 'pre-clinically far outperforming amivantamab and other EGFR CMET'. Not sure if they have seen HNSCC data with those but it very hard for me to believe Genmab did not seriously consider amivantamab competition"
X Link 2025-10-21T18:07Z [---] followers, [---] engagements

"@LuciusJameson i don't know assume they'll wait for the data; we know they have been rather ruthless ditching programs that were not up to their high standards. Remember they also cancelled plans to prodeed with Tisotumab into head/neck it is a field they claim to be very knowledgeable about"
X Link 2025-10-21T18:26Z [---] followers, [--] engagements

"Nearly half of women with hard-to-treat #endometrial cancer responded to Rina-S (#rinatabart sesutecan) in a Phase [--] clinical trial. #Genmab $GMAB https://rarecancernews.com/news/nearly-half-endometrial-cancer-patients-respond-rina-s-trial/utm_source=twitter&utm_medium=shared https://rarecancernews.com/news/nearly-half-endometrial-cancer-patients-respond-rina-s-trial/utm_source=twitter&utm_medium=shared"
X Link 2025-10-22T13:49Z [---] followers, [---] engagements

"#Genmab accelerates its biopharma strategy with #Merus N.V. as the catalyst. by @davidmygind #Genmab $GMAB $MRUS https://www.linkedin.com/posts/mygind-management_genmab-accelerates-its-biopharma-strategy-activity-7386643400768524288-4-Vfutm_source=share&utm_medium=member_desktop&rcm=ACoAAAAXsyQBjCAVt1ELFUq3lJ8Z9TLop0Mc22g https://www.linkedin.com/posts/mygind-management_genmab-accelerates-its-biopharma-strategy-activity-7386643400768524288-4-Vfutm_source=share&utm_medium=member_desktop&rcm=ACoAAAAXsyQBjCAVt1ELFUq3lJ8Z9TLop0Mc22g"
X Link 2025-10-23T10:53Z [---] followers, [---] engagements

"Kesimpta continues strong growth: Q1 [---] mn USD Q2 [-----] Q3 [-----] makes YTD [-----] almost equals full year [----] which was [-----] $NVS $NOVN $GMAB #Genmab 10% Royalty meanwhile Ocrevus growth stalls [----] [----] [----] mn CHF"
X Link 2025-10-28T08:13Z [---] followers, [---] engagements

"#Genmab to Showcase Latest Blood Cancer Treatment Advancements at [----] American Society of Hematology (ASH) Annual Meeting $GMAB #ASH2025 #Epcoritamab #Epkinly $ABBV https://ir.genmab.com/news-releases/news-release-details/genmab-showcase-latest-blood-cancer-treatment-advancements-2025 https://ir.genmab.com/news-releases/news-release-details/genmab-showcase-latest-blood-cancer-treatment-advancements-2025"
X Link 2025-11-03T14:37Z [---] followers, [---] engagements

"#TEPEZZA (teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter driven by higher inventory levels and higher net selling price $AMGN $GMAB #Genmab #Royalties https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results"
X Link 2025-11-05T08:58Z [---] followers, [---] engagements

"From lab coat to Lifestar: Jan van de Winkel shares his success story Before #Genmab's co-founder and CEO collects his Lifetime Achievement Award this November BioXconomy caught up with him for an exclusive chat about his remarkable journey. $GMAB $MRUS https://www.bioxconomy.com/partnering/from-lab-coat-to-lifestar-jan-van-de-winkel-shares-his-success-story https://www.bioxconomy.com/partnering/from-lab-coat-to-lifestar-jan-van-de-winkel-shares-his-success-story"
X Link 2025-11-06T08:34Z [---] followers, [---] engagements

"New #Genmab trial: #Rina-S Plus Standard of Care vs. Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive #Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (#RAINFOL-04) $GMAB #Rinatabart https://clinicaltrials.gov/study/NCT07225270 https://clinicaltrials.gov/study/NCT07225270"
X Link 2025-11-06T15:41Z [---] followers, [---] engagements

"#Genmab A/S Q3 FY2025 earnings call transcript $GMAB https://finance.yahoo.com/quote/GMAB.CO/earnings/GMAB.CO-Q3-2025-earnings_call-315200.htmlerr=1 http://GMAB.CO https://finance.yahoo.com/quote/GMAB.CO/earnings/GMAB.CO-Q3-2025-earnings_call-315200.htmlerr=1 http://GMAB.CO"
X Link 2025-11-07T14:42Z [---] followers, [--] engagements

"#TALVEY (talquetamab) receives positive #NICE recommendation in Final Draft Guidance for treating relapsed and refractory multiple myeloma after three or more lines of treatment $JNJ $GMAB #Genmab #Royalties https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/talvey-talquetamab-receives-positive-nice-recommendation-in-final-draft-guidance-for-treating-relapsed-and-refractory-multiple-myeloma"
X Link 2025-11-18T09:37Z [---] followers, [---] engagements

"the Food and Drug Administration approved #epcoritamab-bysp (#Epkinly Genmab US Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (#FL). $GMAB $ABBV #AbbVie https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications"
X Link 2025-11-18T15:30Z [---] followers, [---] engagements

"#Genmab $GMAB #Royalties As we suspected the Majestec-3 trial of Tecvayli + Darzalex in relapsed multiple myeloma will feature as an #ASH25 late breaker. Toplined positive in Oct https://t.co/ysYcaJCRuG As we suspected the Majestec-3 trial of Tecvayli + Darzalex in relapsed multiple myeloma will feature as an #ASH25 late breaker. Toplined positive in Oct https://t.co/ysYcaJCRuG"
X Link 2025-11-24T16:16Z [---] followers, [---] engagements

"Expert: #Epcoritamab-Based Therapy Reduces Progression Risk in Follicular Lymphoma $GMAB $ABBV #Epkinly https://www.pharmacytimes.com/view/expert-epcoritamab-based-therapy-reduces-progression-risk-in-follicular-lymphoma https://www.pharmacytimes.com/view/expert-epcoritamab-based-therapy-reduces-progression-risk-in-follicular-lymphoma"
X Link 2026-01-09T09:19Z [---] followers, [---] engagements

"RT @IBDinvestors: Biotech Stocks' Dark Winter Is Over. What That Means For Investors. https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/ https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/"
X Link 2026-01-10T12:50Z [---] followers, [--] engagements

"RT @NickTimiraos: The heads of the central banks in Australia Brazil Canada Denmark the Eurozone South Korea Sweden Switzerland the"
X Link 2026-01-13T12:47Z [---] followers, [----] engagements

"RT @Daractenus: Macron: "Ukraine was overwhelmingly dependent on American intelligence capabilities a year ago today two thirds are provid"
X Link 2026-01-15T16:18Z [---] followers, [----] engagements

"SHB: verdriven marknadsreaktion p Genmabs Epkinly-studie -SHB reiterates its buy recommendation https://borsvarlden.com/artiklar/shb-overdriven-marknadsreaktion-pa-genmabs-epkinly-studie https://borsvarlden.com/artiklar/shb-overdriven-marknadsreaktion-pa-genmabs-epkinly-studie"
X Link 2026-01-19T08:23Z [---] followers, [--] engagements

"UBS Maintained Buy dkk 2.750"
X Link 2026-01-19T11:12Z [---] followers, [--] engagements

"RT @Reuters: California Governor Gavin Newsom accused European leaders of complicity towards US President Trump's threats to take over Gr"
X Link 2026-01-20T14:25Z [---] followers, [---] engagements

"AbbVie: #Epkinly sales Q2 [----] $70mn 94% over Q2 [----] $ABBV $GMAB #Genmab #Epcoritamab https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results"
X Link 2025-07-31T15:47Z [---] followers, [---] engagements

"Transcript: #Genmab presentation at the Jefferies Healthcare Conference Fireside Chat with Chief Executive Officer Jan van de Winkel and Chief Financial Officer Anthony Pagano. $GMAB via https://proinvestor.com/investornyt/1385876/transcript-genmabs-praeligsentation-paring-jefferies-healthcare-conference-med-qampa https://proinvestor.com/investornyt/1385876/transcript-genmabs-praeligsentation-paring-jefferies-healthcare-conference-med-qampa"
X Link 2025-11-24T11:55Z [---] followers, [---] engagements

"#Genmab $GMAB #AbbVie $ABBV epcoritamab #Epkinly #Hematology Fixed-duration epcoritamab plus R2 (lenalidomide + rituximab) seems to overcome poorer prognosis in POD24 follicular. Amazing results #lymphoma #lymsm https://t.co/4kC4Vi7xtj #Hematology Fixed-duration epcoritamab plus R2 (lenalidomide + rituximab) seems to overcome poorer prognosis in POD24 follicular. Amazing results #lymphoma #lymsm https://t.co/4kC4Vi7xtj"
X Link 2025-12-01T14:43Z [---] followers, [---] engagements

"#Genmab and #BioNTechs Revolutionary Bispecific Antibody Shows Promising Results (DuoBody -PD-L1x4-1BB) #ASCO24 $GMAB $BNTX #Acasunlimab https://csimarket.com/news/genmab-and-biontech-s-revolutionary-bispecific-antibody-shows-promising-results-i2024-06-01164271 https://csimarket.com/news/genmab-and-biontech-s-revolutionary-bispecific-antibody-shows-promising-results-i2024-06-01164271"
X Link 2024-06-01T19:12Z [---] followers, [----] engagements

"#Lundbeck presents results from [--] studies in Multiple System Atrophy -International Congress of #Parkinson's Disease and Movement Disorders Amlenetug #LuAF82422 is being developed by Lundbeck under a joint research/licensing agreement with @Genmab $GMAB https://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international-congress-of-pc4043552 https://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-results-from-two-studies-in-multiple-system-atrophy-at-international-congress-of-pc4043552"
X Link 2024-09-27T13:20Z [---] followers, [---] engagements

"Lundbeck initiates a phase III trial with #Amlenetug for the treatment of Multiple System Atrophy developed under joint agreement with @Genmab single-digit royalties to $GMAB $1.5-3bn potential market size [----] potential launch #LuAF82422 via @cision https://news.cision.com/h--lundbeck-a-s/r/lundbeck-initiates-a-phase-iii-trial-with-amlenetug-for-the-treatment-of-multiple-system-atrophyc4071927 https://news.cision.com/h--lundbeck-a-s/r/lundbeck-initiates-a-phase-iii-trial-with-amlenetug-for-the-treatment-of-multiple-system-atrophyc4071927"
X Link 2024-11-27T09:19Z [---] followers, [---] engagements

"Lundbecks #Amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA developed under a joint agreement with @Genmab single-digit royalties to $GMAB $1.5-3bn potential market size [----] potential launch #LuAF82422 https://news.cision.com/h--lundbeck-a-s/r/lundbeck-s-potential-treatment-amlenetug-for-multiple-system-atrophy-receives-fast-track-designationc4103999 https://news.cision.com/h--lundbeck-a-s/r/lundbeck-s-potential-treatment-amlenetug-for-multiple-system-atrophy-receives-fast-track-designationc4103999"
X Link 2025-02-12T08:48Z [---] followers, [----] engagements

"Zai Lab announces that #Chinas National Medical Products Administration (NMPA) has accepted the #BLA for #TIVDAK (tisotumab vedotin) for the treatment of patients with recurrent or metastatic #cervical cancer #Genmab #Pfizer $GMAB $PFE https://www.businesswire.com/news/home/20250312721980/en/Zai-Lab-Announces-Acceptance-of-Biologics-License-Application-for-TIVDAK-for-the-Treatment-of-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer"
X Link 2025-03-13T08:16Z [---] followers, [---] engagements

"#Acasunlimab an Fc-inert PD-L14-1BB bispecific antibody combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects $GMAB #Genmab #DuoBody #GEN1046 https://jitc.bmj.com/content/13/4/e011377 https://jitc.bmj.com/content/13/4/e011377"
X Link 2025-04-14T13:35Z [---] followers, [---] engagements

"#Acasunlimab + PD-1 Blockade: Combining Forces to Boost Anti-Tumor Immunotherapy @Genmab $GMAB #GEN1046 #DuoBody-PD-L1x4-1BB https://youtu.be/qcUcA1epnWAfeature=shared https://youtu.be/qcUcA1epnWAfeature=shared"
X Link 2025-05-14T06:57Z [---] followers, [---] engagements

"@ByMadeleineA @ApexOnco Hi Madeleine in your article you refer to BNT322 'now disclosed as an anti-PD-L1 x 4-1BB bispecific'. Can you confirm this is correct (as i can not find this anywhere) or are you possibly confusing it with acasunlimab (GEN1046/BNT311)"
X Link 2025-08-06T08:08Z [---] followers, [---] engagements

"MHRA (UK) approves #tisotumab vedotin for the treatment of cervical cancer #Tivdak #Genmab #Pfizer $GMAB $PFE https://www.gov.uk/government/news/mhra-approves-tisotumab-vedotin-for-the-treatment-of-cervical-cancer https://www.gov.uk/government/news/mhra-approves-tisotumab-vedotin-for-the-treatment-of-cervical-cancer"
X Link 2025-12-02T16:15Z [---] followers, [---] engagements

"Unprecedented results from the Phase [--] MajesTEC-3 study support #TECVAYLI plus #DARZALEX FASPRO as a potential standard of care as early as second line for patients with R/R multiple myeloma $JNJ $GMAB #Genmab #Royalties https://www.jnj.com/media-center/press-releases/unprecedented-results-from-the-phase-3-majestec-3-study-support-tecvayli-plus-darzalex-faspro-as-a-potential-standard-of-care-as-early-as-second-line-for-patients-with-relapsed-refractory-multiple-myeloma"
X Link 2025-12-09T14:23Z [---] followers, [---] engagements

"New #Genmab trial: Study to Assess the Efficacy and Safety of #Rina-S in Participants With Non-small Cell #Lung Cancer (RAINFOL-05) $GMAB #Rinatabart #NSCLC . https://clinicaltrials.gov/study/NCT07288177 https://clinicaltrials.gov/study/NCT07288177"
X Link 2025-12-18T12:03Z [---] followers, [---] engagements

"SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical $GMAB #MarketScreener https://www.marketscreener.com/news/shb-genmab-s-decision-to-halt-acasunlimab-development-deemed-logical-ce7e59dbd180f420utm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/news/shb-genmab-s-decision-to-halt-acasunlimab-development-deemed-logical-ce7e59dbd180f420utm_source=twitter&utm_medium=social&utm_campaign=share"
X Link 2025-12-30T09:20Z [---] followers, [---] engagements

"Morningstar: Best European Stocks for Q1 2026: Our Top Picks by Sector $GMAB Genmab https://global.morningstar.com/en-nd/stocks/best-european-stocks-q1-2026-our-top-picks-by-sector https://global.morningstar.com/en-nd/stocks/best-european-stocks-q1-2026-our-top-picks-by-sector"
X Link 2026-01-09T10:05Z [---] followers, [---] engagements

"Dagens aktie Jyske Bank: #Genmab Spndende ASCO forude $GMAB $BNTX #BioNTech #GEN1046 #Acasunlimab https://www.jyskebank.dk/finansnyt/morgennyt/94b1f65b-b409-486c-a6b3-555fb0ebb10f/ut/p/z1/rVTLcuIwEPyWPXBUSX4gQ27GZAkxLxMIsi6U5QhHiSUTY5ywX78yrq11qGTJVtBFmtGou2tqWpBCAqmKSpFEhchUlOo4pHg9M_u20blDk8GsZ6FgMfJ_zvtzYzF14D0MezDcZg4vArg6V031NfpkuUi_p-dKQk3hfEphG3BVCv4KlyrLpdZ_VyFuY_EAw67NjA1uM8Bs1AV2B8cgwswC7XZ7wxBnzEAbeHOOwUcfMay88TpYXs_1230h13Ekt5FIFAxllidcqUNRX0j-IPYShlxGIq1Tu2yfx1xX6syO56XQwf9pPhHcmd04CI8D2-4tfMPE9jdbcgI_DY7wxnDgm1PLtMzLwp-2G18afmgj7A39hTOZIzy9MHzH7"
X Link 2024-06-04T07:08Z [---] followers, [---] engagements

"EPCORE FL-1: Adding #Epcoritamab to R2 Delivers New Benchmark in Second-Line Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly https://www.ajmc.com/view/epcore-fl-1-adding-epcoritamab-to-r2-delivers-new-benchmark-in-second-line-follicular-lymphoma https://www.ajmc.com/view/epcore-fl-1-adding-epcoritamab-to-r2-delivers-new-benchmark-in-second-line-follicular-lymphoma"
X Link 2025-12-08T08:09Z [---] followers, [---] engagements

"#Epcoritamab offers new hope for patients with #Richter Transformation - one of the most aggressive and difficult-to-treat forms of lymphoma. $GMAB $ABBV @Genmab #AbbVie #Epkinly @amsterdamumc http://www.amsterdamumc.org/en/research/institutes/cancer-center-amsterdam/news/epcoritamab-offers-new-hope-for-patients-with-richter-transformation.htm http://www.amsterdamumc.org/en/research/institutes/cancer-center-amsterdam/news/epcoritamab-offers-new-hope-for-patients-with-richter-transformation.htm"
X Link 2025-12-10T09:18Z [---] followers, [---] engagements

"Deutsche Bank Raises Target Price for Genmab to [----] Danish Kroner (2000) Reiterates Buy $GMAB #MarketScreener https://www.marketscreener.com/news/deutsche-bank-raises-target-price-for-genmab-to-2-400-danish-kroner-2-000-reiterates-buy-ce7d50ddd98ef224utm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/news/deutsche-bank-raises-target-price-for-genmab-to-2-400-danish-kroner-2-000-reiterates-buy-ce7d50ddd98ef224utm_source=twitter&utm_medium=social&utm_campaign=share"
X Link 2025-12-19T12:32Z [---] followers, [---] engagements

"UBS raises Genmab stock price target to DKK2750 on pipeline potential while maintaining a Buy rating on the Danish biotech company. $GMAB https://www.investing.com/news/analyst-ratings/ubs-raises-genmab-stock-price-target-to-dkk2750-on-pipeline-potential-93CH-4436366 https://www.investing.com/news/analyst-ratings/ubs-raises-genmab-stock-price-target-to-dkk2750-on-pipeline-potential-93CH-4436366"
X Link 2026-01-08T09:34Z [---] followers, [---] engagements

"UBS naming Genmab as the firms top pick for European biotech in [----] Other $GMAB analyst changes this week: #Barclays PT to dkk2.500 (from dkk2.000) maintains Overweight #DeutscheBank to [-----] (2.000) reiterated Buy #SEB to [-----] (2.350) repeats Buy UBS raises Genmab stock price target to DKK2750 on pipeline potential while maintaining a Buy rating on the Danish biotech company. $GMAB https://t.co/nurIba2T7o UBS raises Genmab stock price target to DKK2750 on pipeline potential while maintaining a Buy rating on the Danish biotech company. $GMAB https://t.co/nurIba2T7o"
X Link 2026-01-08T12:50Z [---] followers, [---] engagements

"Dr. Marcel Nijland over #epcoritamab met R2 bij R/R folliculair lymfoom #Genmab $GMAB #Epkinly . https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/ https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/"
X Link 2026-01-16T11:57Z [---] followers, [---] engagements

"Danske Aktier - okt [----] Anbefalinger p danske aktier samt Jyske Banks bud p denne mneds over- og underperformere p kort sigt. Overperformere: Royal Unibrew Genmab $GMAB DSV Underperformere: Demant Novo Nordisk https://www.jyskebank.dk/wps/wcm/connect/jfo/2fa1f4e9-90e5-41c0-8af6-d8fd177bdf65/Danske+Aktier+Oktober+2023+f%C3%A6rdig.pdfMOD=AJPERES&CACHEID=ROOTWORKSPACE.Z18_P20418S0N05640Q0MBPDFT1PE7-2fa1f4e9-90e5-41c0-8af6-d8fd177bdf65-oK5iULz"
X Link 2023-11-01T10:55Z [---] followers, [---] engagements

"Wainwright #Buy Rating Affirmed for #Genmab: PT $50 $GMAB Despite BioNTechs decision to step back from co-development of #acasunlimab confidence in the drug remains unshaken as he finds the clinical results from ASCO [----] to be highly encouraging. http://markets.businessinsider.com/news/1033645523 http://markets.businessinsider.com/news/1033645523"
X Link 2024-08-07T06:59Z [---] followers, [---] engagements

"Dosing Regimen for #Acasunlimab (DuoBody-PD-L1x4-1BB) In Combination with Pembrolizumab #Genmab Acasunlimab becomes our 2nd wholly owned candidate medicine entering Ph3 by year end underscoring our strong confidence in the clinical promise and commercial potential $GMAB #WCLC24"
X Link 2024-09-09T06:42Z [---] followers, [---] engagements

"New Phase [--] trial to evaluate the efficacy and safety of #Acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in non-small cell lung cancer #GEN1047 - DuoBody-PD-L1x4-1BB is now fully owned by #Genmab $GMAB https://clinicaltrials.gov/study/NCT06635824 https://clinicaltrials.gov/study/NCT06635824"
X Link 2024-10-10T13:53Z [---] followers, [----] engagements

"2025 European Lung Cancer Congress ABBIL1TY NSCLC-06: A global randomized open-label phase III trial of #Acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel #Genmab $GMAB #ELCC2025 https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/listq=acasunlimab https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/presentation/listq=acasunlimab"
X Link 2025-03-20T14:35Z [---] followers, [---] engagements

"New #Genmab trial: Study of the Effectiveness and Safety of #Acasunlimab Alone and With Pembrolizumab to Treat Advanced #Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) $GMAB https://clinicaltrials.gov/study/NCT06984328 https://clinicaltrials.gov/study/NCT06984328"
X Link 2025-05-22T14:11Z [---] followers, [---] engagements

"#Epcoritamab kan blive en gamechanger i behandlingen af #Richters transformation $GMAB $ABBV @Genmab #AbbVie #Epkinly https://haematologisktidsskrift.dk/sygdomme/sjaeldne-diagnoser/1690-epcoritamab-kan-blive-en-gamechanger-i-behandlingen-af-richters-transformation.html https://haematologisktidsskrift.dk/sygdomme/sjaeldne-diagnoser/1690-epcoritamab-kan-blive-en-gamechanger-i-behandlingen-af-richters-transformation.html"
X Link 2025-12-10T09:45Z [---] followers, [---] engagements

"#Subcutaneous #Amivantamab $JNJ #Genmab $GMAB -- Double Royalties 🔥🚨@OncoAlert Hot off the press ❇The long-awaited #GoodNews: @US_FDA approves: #Subcutaneous #Amivantamab for: 🔷Advanced #EGFRm non-small-cell #LungCancer (in combination with #Lazertinib) based on the #PALOMA3 Trial which showed: ✅Significant #Toxicity https://t.co/8KPD9AoOin 🔥🚨@OncoAlert Hot off the press ❇The long-awaited #GoodNews: @US_FDA approves: #Subcutaneous #Amivantamab for: 🔷Advanced #EGFRm non-small-cell #LungCancer (in combination with #Lazertinib) based on the #PALOMA3 Trial which showed: ✅Significant"
X Link 2025-12-19T07:27Z [---] followers, [---] engagements

"Truist maintains optimism for [----] read-out after Genmabs Phase [--] trial OS miss this outcome does not change the firms view on the key frontline DLBCL study Truist remains optimistic for a positive read-out this year and has a $GMAB Buy PT $48. https://www.tipranks.com/news/the-fly/truist-maintains-optimism-for-2026-read-out-after-genmabs-phase-3-trial-os-miss-thefly https://www.tipranks.com/news/the-fly/truist-maintains-optimism-for-2026-read-out-after-genmabs-phase-3-trial-os-miss-thefly"
X Link 2026-01-16T20:15Z [---] followers, [---] engagements

"Can epcoritamab reshape salvage DLBCL care Genmabs Phase [--] data brings regulatory momentum $GMAB https://pharmadevicenews.com/can-epcoritamab-reshape-salvage-dlbcl-care-genmabs-phase-3-data-brings-regulatory-momentum/ https://pharmadevicenews.com/can-epcoritamab-reshape-salvage-dlbcl-care-genmabs-phase-3-data-brings-regulatory-momentum/"
X Link 2026-01-17T15:53Z [---] followers, [---] engagements

"Analyst Charlie Haywood from Bank of America Securities reiterated a Buy rating on #Genmab and increased the price target to DKK2500 from DKK2250 $GMAB https://www.tipranks.com/news/ratings/maintaining-buy-on-genmab-epkinly-combination-potential-outweighs-monotherapy-setback-ratings https://www.tipranks.com/news/ratings/maintaining-buy-on-genmab-epkinly-combination-potential-outweighs-monotherapy-setback-ratings"
X Link 2026-01-20T08:05Z [---] followers, [---] engagements

"RT @KyivPost: Kyiv is on the brink of a humanitarian catastropheMayor Klitschko In January alone around [------] people left the city. In"
X Link 2026-01-21T10:22Z [---] followers, [----] engagements

"Reisbranche ziet dramatische daling van boekingen naar Verenigde Staten: Het is kommer en kwel https://www.telegraaf.nl/financieel/reisbranche-ziet-dramatische-daling-van-boekingen-naar-verenigde-staten-het-is-kommer-en-kwel/125227862.html https://www.telegraaf.nl/financieel/reisbranche-ziet-dramatische-daling-van-boekingen-naar-verenigde-staten-het-is-kommer-en-kwel/125227862.html"
X Link 2026-01-21T12:18Z [---] followers, [--] engagements

"what a speech. 🔥 Davos 2026: Special Address by Volodymyr Zelenskyy President of Ukraine https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/special-address-by-volodymyr-zelenskyy-president-of-ukraine-3bf6955e08/ https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/special-address-by-volodymyr-zelenskyy-president-of-ukraine-3bf6955e08/"
X Link 2026-01-22T20:09Z [---] followers, [--] engagements

"RT @RepDonBacon: It is beyond time to send Ukraine long-range precision strike weapons. We also should help Ukraine with air defenses and l"
X Link 2026-01-28T13:07Z [---] followers, [----] engagements

"Ahead of the Munich Security Conference I joined @BBCNews to talk international security and Dutch priorities. Ukraine is where our focus should be. Ready for two days packed with diplomacy"
X Link 2026-02-13T11:44Z 59.7K followers, [----] engagements

"📈 Epcoritamab continues to show activity across the #CLL disease spectrum extending its reach into Richter transformation. 📝 Read more from an analysis of the EPCORE CLL-1 trial with insight from Jose Sandoval Sus MD of @MoffittNews. ➡ https://buff.ly/rw42ehk https://buff.ly/rw42ehk"
X Link 2026-02-09T14:01Z [----] followers, [---] engagements

"I am a Ukrainian Nobel Peace Prize Laureate. I have a question. Why has Trump's year of negotiations been the deadliest for civilians in Ukraine since the full-scale invasion The number of deaths and injuries has increased by [--] percent compared to the previous year. Why did Putin not allow himself such brutal strikes on civilian infrastructure under Biden whom Trump calls weak but totally destroys peaceful cities and disregards the strong Trump Photo Liz Landers https://twitter.com/i/web/status/2019056966052499647 https://twitter.com/i/web/status/2019056966052499647"
X Link 2026-02-04T14:34Z 198.7K followers, 1.1M engagements

"During my visit to Kyiv today I saw a civilian heating plant targeted by Russian missiles. No military value whatsoever - attacks meant only to make people suffer. But Ukraine stands strong. And NATO stands with you"
X Link 2026-02-03T18:16Z 112.4K followers, 1.8M engagements

"It is beyond time to send Ukraine long-range precision strike weapons. We also should help Ukraine with air defenses and later mod F-16s that have better radars and jamming capabilities. Russia only responds well to strength and takes advantage of weakness. 🚨 BREAKING NEWS: Sen. Lindsey Graham has called for the United States to "go all in by arming Ukraine with deadly 'Tomahawk cruise missiles' to strike deep inside Russian territory if Putin rejects the peace deal. What's your thoughts on this 🤔 https://t.co/sCsWLQNoWK 🚨 BREAKING NEWS: Sen. Lindsey Graham has called for the United States"
X Link 2026-01-28T12:54Z 89.9K followers, 102.9K engagements

"🚨 BREAKING NEWS: Sen. Lindsey Graham has called for the United States to "go all in by arming Ukraine with deadly 'Tomahawk cruise missiles' to strike deep inside Russian territory if Putin rejects the peace deal. What's your thoughts on this 🤔"
X Link 2026-01-26T14:39Z 32.5K followers, 577.3K engagements

"While talking about Alex Pretti Trump suggests he feels even worse about Renee Good because her parents were Trump fans"
X Link 2026-01-27T21:26Z 714.7K followers, 3.4M engagements

"I read about grandmother Zhenya who froze to death in her apartment in Kyiv. She survived the Holocaust but did not survive this winter. It turns out we were almost neighbors; she lived at Podil. The Russians killed an elderly couple who were trying to evacuate on their own from an occupied village in the Sumy region. The man was pulling his wife on a sled through the snow. First one FPV drone targeted the woman. The second drone attacked the already wounded man who remained next to her body. In the Kharkiv region Russian Shahed drones targeted a passenger train. The car caught fire there"
X Link 2026-01-28T11:40Z 198.7K followers, 207.8K engagements

"Led by Darzalex surge J&J expects revenue to reach $100B in [----] https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026 https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026"
X Link 2026-01-21T18:33Z 99.9K followers, [----] engagements

"Kyiv is on the brink of a humanitarian catastropheMayor Klitschko In January alone around [------] people left the city. In some buildings temperatures are so low that water in toilets has frozen. Without urgent restoration of water supply and sewage systems the risk of epidemics is growing. https://twitter.com/i/web/status/2013733556166541717 https://twitter.com/i/web/status/2013733556166541717"
X Link 2026-01-20T22:01Z 393.7K followers, 393K engagements

"California Governor Gavin Newsom accused European leaders of complicity towards US President Trump's threats to take over Greenland. Speaking on the sidelines of WEF Newsom said it's time to have principles it's time to stand tall and strong https://reut.rs/45PLBhA https://reut.rs/45PLBhA"
X Link 2026-01-20T12:40Z 25M followers, 283.8K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing